Cite
HARVARD Citation
Cohen, E. et al. (n.d.). 316TiPNeoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study. Annals of oncology. p. . [Online].